Real Time
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,8 EUR | -2,44% | +76,60% | -90,17% |
24/04 | Transcript : Vivoryon Therapeutics N.V., 2023 Earnings Call, Apr 24, 2024 | |
24/04 | Vivoryon stopt eerder met studie naar middel tegen Alzheimer | AM |
Omzet 2023 | -3,62K -3,89K | Omzet 2024 * | - | Marktkapitalisatie | 21,37 mln. 22,95 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2023 | -28 mln. -30,06 mln. | Nettowinst (verlies) 2024 * | -18 mln. -19,32 mln. | EV/omzet 2023 | -53.497 x |
Nettoliquiditeiten 2023 | 18,52 mln. 19,89 mln. | Nettoliquiditeiten 2024 * | 19,55 mln. 20,99 mln. | EV/omzet 2024 * | - |
K/w-verhouding 2023 |
-7,27
x | K/w-verhouding 2024 * |
-1,14
x | Werknemers | 15 |
Dividendrendement 2023 * |
-
| Dividendrendement 2024 * |
-
| Vrij verhandelbaar | 66,82% |
Recentste transcriptie over Vivoryon Therapeutics N.V.
1 dag | +0,73% | ||
1 week | +82,34% | ||
Lopende maand | +52,96% | ||
1 maand | +52,96% | ||
3 maanden | -91,04% | ||
6 maanden | -89,54% | ||
Lopend jaar | -89,85% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Frank Weber
CEO | Chief Executive Officer | 64 | 01-01-12 |
Anne Doering
DFI | Director of Finance/CFO | - | - |
Director/Board Member | 56 | 31-08-18 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 74 | 01-01-07 | |
Director/Board Member | 54 | 01-01-07 | |
Anne Doering
DFI | Director of Finance/CFO | - | - |
Datum | Koers | Variatie | Volume |
---|---|---|---|
26-04-24 | 0,8 | -2,44% | 307 992 |
25-04-24 | 0,82 | -8,38% | 1 589 391 |
24-04-24 | 0,895 | +24,31% | 3 324 608 |
23-04-24 | 0,72 | +26,32% | 2 581 230 |
22-04-24 | 0,57 | +25,83% | 546 850 |
Real Time Euronext Amsterdam, 26 april 2024 om 09:00 uur
Meer koersenHerzieningen van WPA
Winst van het jaar - Afwijkingspercentage
Vaira. 1 jan. | Kapi. | |
---|---|---|
-89,85% | 22,9 mln. | |
+1,12% | 42,59 mld. | |
+6,77% | 40,65 mld. | |
+45,26% | 40,57 mld. | |
-11,96% | 26,77 mld. | |
+6,01% | 24,81 mld. | |
-24,92% | 18,17 mld. | |
-3,63% | 11,7 mld. | |
+27,16% | 12,05 mld. | |
+7,30% | 11,1 mld. |